FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894924427> ?p ?o ?g. }

• W2894924427 endingPage "375" @default.
• W2894924427 startingPage "367" @default.
• W2894924427 abstract "To determine whether tumor microenvironments affect the clinical response to anti-PD-1 therapy in non-small cell lung cancer, we investigated the expression level of PD-L1 and tumor infiltrating lymphocytes and elucidate their predictive role. Thirty-eight pretreatment and two post-treatment specimens from 36 advanced, treatment-refractory non-small cell lung cancer patients who underwent PD-1 blockade therapy were analyzed. PD-L1 expression by tumor cells and the distribution of CD3, CD8, CD4, FOXP3 and PD-1 positive tumor infiltrating lymphocytes were immunohistochemically assessed and counted using digital image analyzer. CD3+ and CD8+ T cells were distributed more in PD-L1 positive group compared to PD-L1 negative group. Conversely, EGFR mutant group showed fewer CD3+ T cells than EGFR-naïve group. The patients in the clinical benefit group with PD-1 blockade showed a higher number of CD3+, CD8+ T cells and a higher CD8+/CD3+ T cell ratio (p = 0.003, p = 0.001, and p = 0.042) and a lower FOXP3+/CD8+ T cell ratio compared to non-responders (p = 0.001). In multivariate logistic regression analysis, increased CD3+ T cell infiltration and low FOXP3+/CD8+ T cell ratio were found to be independent predictors of clinical benefit with PD-1 blockade (p = 0.014 and p = 0.03, respectively). Using receiver operating characteristic curves, levels of CD3+ T cells and FOXP3+/CD8+ T cell ratio that provide the best distinguishing point between responder versus non-responder to PD-1 blockade were 617.5/mm2 and 25%, respectively (p = 0.007 and p = 0.003). Considering that 1 mm2 is about 5 high power fields (HPF), a good response to the PD-1 blockade can be expected when the number of CD3 T cells is observed to be 120 per HPF and when CD8+ T cells and FOXP3+ T cells are present at a ratio greater than 4:1. Tumor infiltrating lymphocytes might become a promising biomarker as an independent predictive factor of response to PD-1 blockade that may also guide therapeutic decisions." @default.
• W2894924427 created "2018-10-12" @default.
• W2894924427 creator A5001356432 @default.
• W2894924427 creator A5013686145 @default.
• W2894924427 creator A5032303273 @default.
• W2894924427 creator A5044075250 @default.
• W2894924427 creator A5046733038 @default.
• W2894924427 creator A5062716517 @default.
• W2894924427 creator A5063587278 @default.
• W2894924427 creator A5070586345 @default.
• W2894924427 creator A5086784581 @default.
• W2894924427 date "2018-10-08" @default.
• W2894924427 modified "2023-10-17" @default.
• W2894924427 title "Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients" @default.
• W2894924427 cites W1522859339 @default.
• W2894924427 cites W1827997917 @default.
• W2894924427 cites W1889335134 @default.
• W2894924427 cites W1896351481 @default.
• W2894924427 cites W1967060514 @default.
• W2894924427 cites W1982488143 @default.
• W2894924427 cites W2019607817 @default.
• W2894924427 cites W2024384252 @default.
• W2894924427 cites W2039123767 @default.
• W2894924427 cites W2044401440 @default.
• W2894924427 cites W2099609050 @default.
• W2894924427 cites W2104347254 @default.
• W2894924427 cites W2109485845 @default.
• W2894924427 cites W2124427232 @default.
• W2894924427 cites W2128640763 @default.
• W2894924427 cites W2138134458 @default.
• W2894924427 cites W2140633375 @default.
• W2894924427 cites W2145411470 @default.
• W2894924427 cites W2150678612 @default.
• W2894924427 cites W2156353875 @default.
• W2894924427 cites W2165623281 @default.
• W2894924427 cites W2198093519 @default.
• W2894924427 cites W2279684443 @default.
• W2894924427 cites W2302126436 @default.
• W2894924427 cites W2302719382 @default.
• W2894924427 cites W2308639964 @default.
• W2894924427 cites W2344037260 @default.
• W2894924427 cites W2400514548 @default.
• W2894924427 cites W2467854262 @default.
• W2894924427 cites W2478891054 @default.
• W2894924427 cites W2533662151 @default.
• W2894924427 cites W2559382297 @default.
• W2894924427 cites W2561926137 @default.
• W2894924427 cites W2569740680 @default.
• W2894924427 cites W2578528809 @default.
• W2894924427 cites W2737044461 @default.
• W2894924427 cites W2762732298 @default.
• W2894924427 cites W2766425839 @default.
• W2894924427 cites W2786665544 @default.
• W2894924427 doi "https://doi.org/10.1038/s41379-018-0142-3" @default.
• W2894924427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30297881" @default.
• W2894924427 hasPublicationYear "2018" @default.
• W2894924427 type Work @default.
• W2894924427 sameAs 2894924427 @default.
• W2894924427 citedByCount "30" @default.
• W2894924427 countsByYear W28949244272019 @default.
• W2894924427 countsByYear W28949244272020 @default.
• W2894924427 countsByYear W28949244272021 @default.
• W2894924427 countsByYear W28949244272022 @default.
• W2894924427 countsByYear W28949244272023 @default.
• W2894924427 crossrefType "journal-article" @default.
• W2894924427 hasAuthorship W2894924427A5001356432 @default.
• W2894924427 hasAuthorship W2894924427A5013686145 @default.
• W2894924427 hasAuthorship W2894924427A5032303273 @default.
• W2894924427 hasAuthorship W2894924427A5044075250 @default.
• W2894924427 hasAuthorship W2894924427A5046733038 @default.
• W2894924427 hasAuthorship W2894924427A5062716517 @default.
• W2894924427 hasAuthorship W2894924427A5063587278 @default.
• W2894924427 hasAuthorship W2894924427A5070586345 @default.
• W2894924427 hasAuthorship W2894924427A5086784581 @default.
• W2894924427 hasBestOaLocation W28949244271 @default.
• W2894924427 hasConcept C114684123 @default.
• W2894924427 hasConcept C126322002 @default.
• W2894924427 hasConcept C142724271 @default.
• W2894924427 hasConcept C154317977 @default.
• W2894924427 hasConcept C167672396 @default.
• W2894924427 hasConcept C185592680 @default.
• W2894924427 hasConcept C202751555 @default.
• W2894924427 hasConcept C203014093 @default.
• W2894924427 hasConcept C2776090121 @default.
• W2894924427 hasConcept C2776256026 @default.
• W2894924427 hasConcept C2778326572 @default.
• W2894924427 hasConcept C2779727006 @default.
• W2894924427 hasConcept C55493867 @default.
• W2894924427 hasConcept C71924100 @default.
• W2894924427 hasConcept C8891405 @default.
• W2894924427 hasConceptScore W2894924427C114684123 @default.
• W2894924427 hasConceptScore W2894924427C126322002 @default.
• W2894924427 hasConceptScore W2894924427C142724271 @default.
• W2894924427 hasConceptScore W2894924427C154317977 @default.
• W2894924427 hasConceptScore W2894924427C167672396 @default.
• W2894924427 hasConceptScore W2894924427C185592680 @default.
• W2894924427 hasConceptScore W2894924427C202751555 @default.
• W2894924427 hasConceptScore W2894924427C203014093 @default.

• next